Chardan Capital restated their buy rating on shares of Unity Biotechnology (NASDAQ:UBX – Free Report) in a report issued on Wednesday,Benzinga reports. The brokerage currently has a $4.00 target price ...

Unity Biotechnology (NASDAQ:UBX – Get Free Report) was downgraded by Mizuho from an “outperform” rating to a “neutral” rating in a research note issued to investors on Friday, MarketBeat.com reports.

Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ...

UNITY Biotechnology, Inc. reported its financial results for the first quarter of 2025, highlighting the 24-week and partial 36-week topline data from its Phase 2b ASPIRE study in diabetic macular ...

Unity Biotechnology (OTC:UNBX) Stock, Option Chain Option chain shows key data for Unity Biotechnology's stock options at various strike prices and expiration dates. Traders use this information to ...

UNITY Biotechnology, Inc. has announced that it will present data from its ASPIRE Phase 2B study on its senolytic candidate, UBX1325, targeting diabetic macular edema at the upcoming ARVO 2025 Annual ...